Genscript BiotechGNNSF 66 FCF Margin % is 10.97% as of Dec. 2025. GuruFocus rates GNNSF with a GF Score™ of 66/100 and a GF Value™ of $2.48 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 954 Biotechnology companies, Genscript Biotech ranks better than 91.3% on this metric.
The historical rank and industry rank for Genscript Biotech's FCF Margin % or its related term are showing as below:
GNNSF'
s FCF Margin % Range Over the Past 10 Years
Min: -79.33 Med: -31.96 Max: 98.72
Current: 25.19
During the past 12 years, the highest FCF Margin % of Genscript Biotech was 98.72%. The lowest was -79.33%. And the median was -31.96%.
GNNSF's FCF Margin % is ranked better than 91.3% of 954
companies
in the Biotechnology industry
Industry Median: -84.535
vs GNNSF: 25.19
Genscript Biotech FCF Margin % Related Terms
Genscript Biotech FCF Margin % Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNNSF vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Genscript Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech (GNNSF) has a FCF Margin % of 10.97% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Genscript Biotech and its competitors. According to the industry distribution chart, Genscript Biotech ranks #83 out of 954 companies in the Biotechnology industry, placing it in the top 8.7%.
Is Genscript Biotech's FCF Margin % too high?
Genscript Biotech's current FCF Margin % is 10.97%. Based on the distribution chart, Genscript Biotech ranks #83 out of 954 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genscript Biotech has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #83 out of 954 companies for FCF Margin %. This places Genscript Biotech in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Genscript Biotech and its competitors. Genscript Biotech's current FCF Margin % is 10.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.48, compared to a current price of $1.60 — trading 35.5% below its estimated fair value. The current FCF Margin % is 10.97%. Genscript Biotech's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current FCF Margin % is 10.97% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued.
The current stock price of $1.60 is trading 35.5% below its estimated GF Value™ of $2.48.
GuruFocus considers Genscript Biotech to be Significantly Undervalued.
Key valuation signals for GNNSF:
FCF Margin %: 10.97%
GF Value™: $2.48 vs. price of $1.60 (35.5% below fair value)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
66GF Score
Get the complete analysis for GNNSF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
